BACKGROUND: The brain mechanisms of cognitive-behavioral therapy (CBT), a highly effective treatment for pediatric obsessive-compulsive disorder (OCD), are unknown. Neuroimaging in adult OCD indicates that CBT is associated with metabolic changes in striatum, thalamus, and anterior cingulate cortex. We therefore probed putative metabolic effects of CBT on these brain structures in pediatric OCD using proton magnetic resonance spectroscopic imaging (1H MRSI). METHOD: Five unmedicated OCD patients (4 ♀, 13.5±2.8) and 9 healthy controls (7 ♀, 13.0±2.5) underwent MRSI (1.5 T, repetition-time/echo-time=1500/30 ms) of bilateral putamen, thalamus and pregenual anterior cingulate cortex (pACC). Patients were rescanned after 12 weeks of exposure-based CBT. The Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) of OCD symptoms was administered before and after CBT. RESULTS: Four of 5 patients responded to CBT (mean 32.8% CY-BOCS reduction). Multiple metabolite effects emerged. Pre-CBT, N-acetyl-aspartate+N-acetyl-aspartyl-glutamate (tNAA) in left pregenual anterior cingulate cortex (pACC) was 55.5% higher in patients than controls. Post-CBT, tNAA (15.0%) and Cr (23.9%) in left pACC decreased and choline compounds (Cho) in right thalamus increased (10.6%) in all 5 patients. In left thalamus, lower pre-CBT tNAA, glutamate+glutamine (Glx), and myo-inositol (mI) predicted greater post-CBT drop in CY-BOCS (r=0.98) and CY-BOCS decrease correlated with increased Cho. CONCLUSIONS: Interpretations are offered in terms of the Glutamatergic Hypothesis of Pediatric OCD. Similar to 18FDG-PET in adults, objectively measurable regional MRSI metabolites may indicate pediatric OCD and predict its response to CBT.
BACKGROUND: The brain mechanisms of cognitive-behavioral therapy (CBT), a highly effective treatment for pediatric obsessive-compulsive disorder (OCD), are unknown. Neuroimaging in adult OCD indicates that CBT is associated with metabolic changes in striatum, thalamus, and anterior cingulate cortex. We therefore probed putative metabolic effects of CBT on these brain structures in pediatric OCD using proton magnetic resonance spectroscopic imaging (1HMRSI). METHOD: Five unmedicated OCDpatients (4 ♀, 13.5±2.8) and 9 healthy controls (7 ♀, 13.0±2.5) underwent MRSI (1.5 T, repetition-time/echo-time=1500/30 ms) of bilateral putamen, thalamus and pregenual anterior cingulate cortex (pACC). Patients were rescanned after 12 weeks of exposure-based CBT. The Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) of OCD symptoms was administered before and after CBT. RESULTS: Four of 5 patients responded to CBT (mean 32.8% CY-BOCS reduction). Multiple metabolite effects emerged. Pre-CBT, N-acetyl-aspartate+N-acetyl-aspartyl-glutamate (tNAA) in left pregenual anterior cingulate cortex (pACC) was 55.5% higher in patients than controls. Post-CBT, tNAA (15.0%) and Cr (23.9%) in left pACC decreased and choline compounds (Cho) in right thalamus increased (10.6%) in all 5 patients. In left thalamus, lower pre-CBT tNAA, glutamate+glutamine (Glx), and myo-inositol (mI) predicted greater post-CBT drop in CY-BOCS (r=0.98) and CY-BOCS decrease correlated with increased Cho. CONCLUSIONS: Interpretations are offered in terms of the Glutamatergic Hypothesis of Pediatric OCD. Similar to 18FDG-PET in adults, objectively measurable regional MRSI metabolites may indicate pediatric OCD and predict its response to CBT.
Authors: Murat Yücel; Ben J Harrison; Stephen J Wood; Alex Fornito; Robert M Wellard; Jesus Pujol; Kerrie Clarke; Mary L Phillips; Michael Kyrios; Dennis Velakoulis; Christos Pantelis Journal: Arch Gen Psychiatry Date: 2007-08
Authors: J O'Neill; J L Eberling; N Schuff; W Jagust; B Reed; G Soto; F Ezekiel; G Klein; M W Weiner Journal: Magn Reson Med Date: 2000-02 Impact factor: 4.668
Authors: Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi Journal: Neuropsychopharmacology Date: 2017-04-04 Impact factor: 7.853
Authors: Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch Journal: Neuropsychopharmacology Date: 2015-02-09 Impact factor: 7.853
Authors: Joseph O'Neill; Mary J O'Connor; Victor Yee; Ronald Ly; Katherine Narr; Jeffrey R Alger; Jennifer G Levitt Journal: Birth Defects Res Date: 2019-01-29 Impact factor: 2.344
Authors: Edoardo F Q Vattimo; Vivian B Barros; Guaraci Requena; João R Sato; Daniel Fatori; Euripedes C Miguel; Roseli G Shavitt; Marcelo Q Hoexter; Marcelo C Batistuzzo Journal: Eur Child Adolesc Psychiatry Date: 2019-04-10 Impact factor: 4.785
Authors: Helen Blair Simpson; Lawrence S Kegeles; Liane Hunter; Xiangling Mao; Page Van Meter; Xiaoyan Xu; Marcia B Kimeldorf; Sarah L Pearlstein; Mark Slifstein; Dikoma C Shungu Journal: Psychiatry Res Date: 2015-02-03 Impact factor: 3.222
Authors: Joseph O'Neill; Tsz M Lai; Courtney Sheen; Giulia C Salgari; Ronald Ly; Casey Armstrong; Susanna Chang; Jennifer G Levitt; Noriko Salamon; Jeffry R Alger; Jamie D Feusner Journal: Psychiatry Res Neuroimaging Date: 2016-05-24 Impact factor: 2.376